StockData
enVVeno Medical Corp logo

enVVeno Medical Corp (NVNO) stock

NVNONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 6/30
$5.77+0.00 (0.00%)

Close on Nov 18, 2026Market cap $4.01MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$4.01M
P/E ratio
–
Price to sales
–
Price to book
0.24
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$15.55M
EPS, diluted
-$23.56
Free cash flow
-$15.57M
Book value per share
$24.35
Diluted shares
1M

Trading

Previous close
$5.77
Open
$5.77
Day's range
$5.53 – $6.30
Volume
18,105
Average volume (20 days)
27,593
Beta (5 years)
1.21
52-week range
$5.53 – $14.67
RSI (14 days)
28.7
Volatility (1 year)
79.8%
Relative volume
0.67×
WACC
11.1%

Market cap history

Month-end market cap since 2018, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.

PeriodNVNOS&P 500DifferenceNVNO per yearS&P 500 per year
1 month-22.8%-4.3%−18.4 pts
3 months-47.7%-4.6%−43.1 pts
Year to date-48.6%+7.9%−56.5 pts
1 year-50.0%+11.8%−61.8 pts
3 years-96.1%+68.0%−164.0 pts-66.0%+18.9%
5 years-97.7%+66.2%−163.9 pts-53.0%+10.7%

Ten years at a glance

Fiscal years 2016 to 2025 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$16.41M

Net income

-$15.55M

EPS, diluted

-$23.56

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases enVVeno Medical filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About enVVeno Medical

Surgical & Medical Instruments & Apparatus

enVVeno Medical Corporation is a medical device company developing tissue-based bioprosthetic solutions to treat venous disease, specifically targeting patients with severe chronic venous insufficiency of the deep venous system. The company develops replacement venous valves to restore unidirectional blood flow toward the heart and lungs, counteracting blood pooling and high venous pressure in the lower legs. Its primary product pipeline centers on the enVVe System, a transcatheter, non-surgical replacement valve that includes a delivery device, accessories, nose cone, and crimping mechanism. The device aims to serve patients suffering from severe chronic venous insufficiency and related leg ulcers, with implant procedures intended for vascular surgeons, interventional radiologists, and interventional cardiologists.

Company profile, executives and history

enVVeno Medical stock: common questions

What is enVVeno Medical's stock price?

NVNO closed at $5.77 on Nov 18, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $5.53 and $14.67.

What is enVVeno Medical's market cap?

enVVeno Medical was worth $4.01M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.

What is NVNO's P/E ratio?

enVVeno Medical lost money over the twelve months to Sep 30, 2026 (diluted EPS -$23.56), so it has no meaningful P/E ratio.

Does enVVeno Medical pay a dividend?

No. enVVeno Medical has not paid a cash dividend over the last twelve months.

How has NVNO stock performed over the past year?

Including dividends, NVNO returned -50.0% over the past year, against +11.8% for the S&P 500.

How many NVNO shares are sold short?

0M shares were sold short at the latest FINRA report, 3.87% of the float, or 1.0 days of average trading volume.

Who are enVVeno Medical's competitors?

Companies most similar to enVVeno Medical by business, industry and size include NSPR, PEN, LMAT, ADGM, EBRCZ.

See a number that looks wrong?